Trade Synaptogenix, Inc. - SNPX CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
| Spread | - | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.024068% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.001846% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 20% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
| Prev. Close* | N/A |
| Open* | N/A |
| 1-Year Change* | N/A |
| Day's Range* | N/A |
| 52 wk Range | 0.80-8.75 |
| Average Volume (10 days) | 70.74K |
| Average Volume (3 months) | 1.84M |
| Market Cap | 6.10M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 6.85M |
| Revenue | N/A |
| EPS | -2.07 |
| Dividend (Yield %) | N/A |
| Beta | -100.00K |
| Next Earnings Date | N/A |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|
Synaptogenix, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| No events scheduled | ||
- Annual
- Quarterly
| 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 |
| Total Operating Expense | 12.6183 | 12.8564 | 15.5135 | 11.1494 |
| Selling/General/Admin. Expenses, Total | 8.28189 | 8.08738 | 10.9725 | 6.26383 |
| Research & Development | 4.33641 | 3.06903 | 4.54095 | 4.88556 |
| Operating Income | -12.6183 | -12.8564 | -15.5135 | -11.1494 |
| Interest Income (Expense), Net Non-Operating | 0.00711 | 0.15321 | 0.37871 | 0.12711 |
| Net Income Before Taxes | -12.6112 | -12.7032 | -15.1348 | -11.0223 |
| Net Income After Taxes | -12.6112 | -12.7032 | -15.1348 | -11.0223 |
| Net Income Before Extra. Items | -12.6112 | -12.7032 | -15.1348 | -11.0223 |
| Net Income | -12.6112 | -12.7032 | -15.1348 | -11.0223 |
| Income Available to Common Excl. Extra. Items | -12.6112 | -15.1302 | -15.1348 | -11.0223 |
| Income Available to Common Incl. Extra. Items | -12.6112 | -15.1302 | -15.1348 | -11.0223 |
| Diluted Net Income | -12.6112 | -15.1302 | -15.1348 | -11.0223 |
| Diluted Weighted Average Shares | 5.0151 | 1.25758 | 1.32211 | 1.32211 |
| Diluted EPS Excluding Extraordinary Items | -2.51465 | -12.0312 | -11.4474 | -8.33687 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | |
| Diluted Normalized EPS | -2.51465 | -10.6794 | -11.4474 | -8.33687 |
| Unusual Expense (Income) | 0 | 1.7 | ||
| Total Adjustments to Net Income | -2.427 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 3.28253 | 4.23856 | 2.92938 | 2.29517 | 3.15519 |
| Selling/General/Admin. Expenses, Total | 1.79646 | 2.87693 | 2.09266 | 1.30889 | 2.00341 |
| Research & Development | 1.48607 | 1.36164 | 0.83672 | 0.98628 | 1.15178 |
| Operating Income | -3.28253 | -4.23856 | -2.92938 | -2.29517 | -3.15519 |
| Interest Income (Expense), Net Non-Operating | 0.00461 | 0.00252 | 0.00245 | 0.00133 | 0.00082 |
| Net Income Before Taxes | -3.27792 | -4.23605 | -2.92693 | -2.29384 | -3.15438 |
| Net Income After Taxes | -3.27792 | -4.23605 | -2.92693 | -2.29384 | -3.15438 |
| Net Income Before Extra. Items | -3.27792 | -4.23605 | -2.92693 | -2.29384 | -3.15438 |
| Net Income | -3.27792 | -4.23605 | -2.92693 | -2.29384 | -3.15438 |
| Income Available to Common Excl. Extra. Items | -3.27792 | -4.23605 | -2.92693 | -2.29384 | -3.15438 |
| Income Available to Common Incl. Extra. Items | -3.27792 | -4.23605 | -2.92693 | -2.29384 | -3.15438 |
| Diluted Net Income | -3.27792 | -4.23605 | -2.92693 | -2.29384 | -3.15438 |
| Diluted Weighted Average Shares | 6.9392 | 6.7998 | 6.1966 | 3.9712 | 2.96903 |
| Diluted EPS Excluding Extraordinary Items | -0.47238 | -0.62297 | -0.47234 | -0.57762 | -1.06243 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.47238 | -0.62297 | -0.47234 | -0.57762 | -1.06243 |
| Unusual Expense (Income) | 0 |
- Annual
- Quarterly
| 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|
| Total Current Assets | 35.5042 | 6.72879 | 17.8762 | 29.4575 |
| Cash and Short Term Investments | 34.214 | 5.79506 | 17.382 | 28.8542 |
| Cash & Equivalents | 34.214 | 5.79506 | 17.382 | 28.8542 |
| Prepaid Expenses | 1.29023 | 0.80629 | 0.49411 | 0.60332 |
| Total Assets | 35.5247 | 6.751 | 17.8978 | 29.4784 |
| Property/Plant/Equipment, Total - Net | 0.02045 | 0.02221 | 0.02167 | 0.02084 |
| Total Current Liabilities | 1.99491 | 1.61249 | 0.47906 | 2.95708 |
| Accounts Payable | 1.29651 | 1.26034 | 0.41308 | 2.89858 |
| Accrued Expenses | 0.69841 | 0.35215 | 0.06598 | 0.05849 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 |
| Total Liabilities | 1.99491 | 1.61249 | 0.47906 | 2.95708 |
| Total Long Term Debt | 0 | 0 | 0 | 0 |
| Total Equity | 33.5298 | 5.13851 | 17.4188 | 26.5213 |
| Common Stock | 0.00067 | 0.0005 | 0.00131 | 0.00129 |
| Additional Paid-In Capital | 47.6707 | 6.66848 | 106.234 | 100.202 |
| Retained Earnings (Accumulated Deficit) | -14.1417 | -1.53047 | -88.8168 | -73.6821 |
| Total Liabilities & Shareholders’ Equity | 35.5247 | 6.751 | 17.8978 | 29.4784 |
| Total Common Shares Outstanding | 6.73018 | 1.25758 | 1.32211 | 1.32211 |
| Total Receivables, Net | 0.12745 | |||
| Other Equity, Total | 0 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Total Current Assets | 32.3342 | 35.5042 | 32.3402 | 32.9402 | 16.3257 |
| Cash and Short Term Investments | 31.2817 | 34.214 | 31.2946 | 31.7021 | 14.8484 |
| Cash & Equivalents | 31.2817 | 34.214 | 31.2946 | 31.7021 | 14.8484 |
| Total Receivables, Net | 0 | 0 | |||
| Prepaid Expenses | 1.05247 | 1.29023 | 1.04551 | 1.23816 | 1.47723 |
| Total Assets | 32.3533 | 35.5247 | 32.3586 | 32.96 | 16.3466 |
| Property/Plant/Equipment, Total - Net | 0.01913 | 0.02045 | 0.01849 | 0.01973 | 0.02097 |
| Total Current Liabilities | 0.66934 | 1.99491 | 1.00733 | 0.76997 | 0.93744 |
| Accounts Payable | 0.40135 | 1.29651 | 0.93538 | 0.64816 | 0.75896 |
| Accrued Expenses | 0.26799 | 0.69841 | 0.07195 | 0.12181 | 0.17848 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 0.66934 | 1.99491 | 1.00733 | 0.76997 | 0.93744 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 31.684 | 33.5298 | 31.3513 | 32.19 | 15.4092 |
| Common Stock | 0.00068 | 0.00067 | 0.00062 | 0.0006 | 0.0014 |
| Additional Paid-In Capital | 49.1029 | 47.6707 | 41.2563 | 39.1681 | 20.0927 |
| Retained Earnings (Accumulated Deficit) | -17.4196 | -14.1417 | -9.90563 | -6.97869 | -4.68485 |
| Total Liabilities & Shareholders’ Equity | 32.3533 | 35.5247 | 32.3586 | 32.96 | 16.3466 |
| Total Common Shares Outstanding | 6.80965 | 6.73018 | 6.13697 | 6.0388 | 3.50813 |
- Annual
- Quarterly
| 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|
| Net income/Starting Line | -12.6112 | -12.7032 | -15.1348 | -11.0223 |
| Cash From Operating Activities | -8.71073 | -8.1024 | -11.8868 | -7.69677 |
| Cash From Operating Activities | 0.00497 | 0.00487 | 0.00439 | 0.003 |
| Non-Cash Items | 3.86958 | 3.90212 | 5.61236 | 2.21661 |
| Changes in Working Capital | 0.02593 | 0.69381 | -2.36881 | 1.10591 |
| Cash From Investing Activities | -0.0032 | -0.00541 | -0.00521 | -0.00319 |
| Capital Expenditures | -0.0032 | -0.00541 | -0.00521 | -0.00319 |
| Cash From Financing Activities | 37.1329 | -3.47917 | 0.41984 | 20.441 |
| Issuance (Retirement) of Stock, Net | 37.1344 | 16.5242 | 0.41984 | 20.441 |
| Net Change in Cash | 28.4189 | -11.587 | -11.4722 | 12.7411 |
| Financing Cash Flow Items | -0.00153 | -20.0034 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -3.27792 | -12.6112 | -8.37515 | -5.44822 | -3.15438 |
| Cash From Operating Activities | -3.48541 | -8.71073 | -6.66556 | -5.58532 | -3.58672 |
| Cash From Operating Activities | 0.00132 | 0.00497 | 0.00373 | 0.00249 | 0.00125 |
| Non-Cash Items | 0.87901 | 3.86958 | 2.4228 | 1.1348 | 0.91241 |
| Changes in Working Capital | -1.08781 | 0.02593 | -0.71694 | -1.27439 | -1.34599 |
| Cash From Investing Activities | -0.0032 | 0 | 0 | 0 | |
| Capital Expenditures | -0.0032 | 0 | 0 | 0 | |
| Cash From Financing Activities | 0.55315 | 37.1329 | 32.1651 | 31.4923 | 12.6401 |
| Financing Cash Flow Items | 0 | -0.00153 | -0.00153 | 0.12592 | 0.12745 |
| Issuance (Retirement) of Stock, Net | 0.55315 | 37.1344 | 32.1667 | 31.3664 | 12.5127 |
| Net Change in Cash | -2.93226 | 28.4189 | 25.4996 | 25.907 | 9.0534 |
| Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
|---|---|---|---|---|---|---|
| Alpha Capital Aktiengesellschaft | Holding Company | 4.1055 | 301977 | -29305 | 2021-12-31 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 3.0271 | 222654 | 159 | 2022-12-31 | LOW |
| Intracoastal Capital, L.L.C. | Corporation | 2.4304 | 178765 | 178365 | 2022-12-31 | MED |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.8472 | 62316 | -159 | 2022-12-31 | LOW |
| Perry (George) | Individual Investor | 0.5438 | 40000 | 40000 | 2021-07-13 | |
| Silverman (Joshua) | Individual Investor | 0.5199 | 38238 | 33238 | 2022-12-20 | LOW |
| Alkon (Daniel L M.D.) | Individual Investor | 0.4833 | 35547 | 34062 | 2022-12-20 | |
| Citadel Advisors LLC | Hedge Fund | 0.4655 | 34238 | 34238 | 2022-12-31 | HIGH |
| Weinstein (Robert) | Individual Investor | 0.4513 | 33198 | 33000 | 2022-12-20 | HIGH |
| Singer (William S) | Individual Investor | 0.4487 | 33000 | 33000 | 2022-12-20 | HIGH |
| Tuchman (Alan J) | Individual Investor | 0.4487 | 33000 | 33000 | 2022-12-20 | LOW |
| Cannell & Co. | Investment Advisor | 0.4079 | 30000 | -46220 | 2022-12-31 | LOW |
| Bernstein (Bruce T.) | Individual Investor | 0.3749 | 27578 | 27500 | 2022-12-20 | LOW |
| Schechter (Jonathan L) | Individual Investor | 0.3705 | 27250 | 24750 | 2022-12-20 | HIGH |
| Diametric Capital | Investment Advisor/Hedge Fund | 0.3609 | 26549 | -1172 | 2022-09-30 | HIGH |
| Platform Technology Partners LLC | Investment Advisor | 0.3418 | 25138 | 9106 | 2022-12-31 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.2733 | 20100 | 0 | 2022-12-31 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.2065 | 15188 | 348 | 2022-12-31 | LOW |
| Renaissance Technologies LLC | Hedge Fund | 0.1835 | 13500 | -3000 | 2022-12-31 | HIGH |
| Advisor Group, Inc | Investment Advisor | 0.1244 | 9148 | 8600 | 2022-12-31 | LOW |
Why choose Capital.com? Our numbers speak for themselves.
Capital.com Group500K+
Traders
92K+
Active clients monthly
$53M+
Monthly investing volume
$30M+
Withdrawn each month
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Synaptogenix, Inc. Company profile
Synaptogenix, Inc. (SNPX) is a clinical-stage biotech company. The company leverages Bryostatin-1 and its equivalents to develop drugs and novel therapeutics for patients suffering from neurodegenerative diseases and developmental disorders.
Headquartered in New York, US, Synaptogenix was founded in 2012. As of June 2022 the company is conducting a Phase 2b clinical trial of Bryostatin-1 in patients suffering from moderate to severe Alzheimer’s disease. The project is sponsored by the National Institutes of Health (NIH). The company also receives funding and support from the Blanchette Rockefeller Neurosciences Institute.
Synaptogenix’s product pipeline includes synaptogenic treatment approaches for fragile X syndrome, autism, multiple sclerosis, parkinson’s disease, traumatic brain injury and stroke. The company has licensing agreements with Stanford University and Icahn School of Medicine.
The US Food and Drug Administration (FDA) has granted Bryostatin-1 an Orphan Drug Designation for its regenerative mechanisms of action in the fragile X syndrome case.
The company went public in 2021 on the NASDAQ stock exchange. Synaptogenix, Inc. stock is trading under the ticker symbol SNPX.
You can follow live SNPX stock price movements and price history and keep up with the latest SNPX share value at Capital.com
| Industry: | Biotechnology & Medical Research (NEC) |
1185 Avenue Of The Americas, 3Rd Floor
NEW YORK
NEW YORK 10036
US
Income Statement
- Annual
- Quarterly
News
GBP/EUR forecast: Will the pound rise against the euro in 2023?
The British pound has been moving sideways against the Euro, yet can it regain momentum? Read on for a GBP/EUR forecast.
16:27, 24 March 2023
Shiba Inu price prediction: Can the meme coin build on recent gains?
What’s next for the Shiba Inu meme coin after a sluggish 2022 so far? Read more…
12:51, 24 March 2023
Who are the biggest bitcoin mining companies?
Bitcoin mining is big business, but who are the biggest bitcoin mining companies?
12:06, 24 March 2023
USD/PKR forecast: Will Pakistan’s rupee continue to fall?
The rupee has rebounded against the dollar in recent months, will this trend continue?
11:49, 24 March 2023
Amazon stock forecast: Where next for AMZN amid massive layoffs?
Amazon has been making tens of thousands of its workers redundant. Does this affect the market’s baseline Amazon stock forecast?
10:46, 24 March 2023
Sweatcoin price prediction: What is Sweatcoin?
Can Sweatcoin run to the front of the crypto pack?
15:19, 23 March 2023
Who owns the most bitcoin?
Want to know who owns the most bitcoin? Learn more about the biggest bitcoin whales.
14:54, 23 March 2023People also watch
Still looking for a broker you can trust?
Join the 500.000+ traders worldwide that chose to trade with Capital.com